Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1Dermatologic 1

Conditions

Neoplasms 1Neoplasm Metastasis 1Hepatitis C 1Hepatitis B 1Fibrosis 1Carcinoma, Hepatocellular 1

Interventions

Fluorouracil 126Leucovorin 90Oxaliplatin 82Specimen Handling 71Gemcitabine 61Magnetic Resonance Spectroscopy 55Irinotecan 55Biopsy 53Capecitabine 40Bevacizumab 40Radiotherapy 37Cisplatin 34Cetuximab 29Chemotherapy, Adjuvant 28Erlotinib Hydrochloride 26Neoadjuvant Therapy 21dehydroftorafur 20Cyclophosphamide 19Nivolumab 18Sorafenib 17Radiation 17Paclitaxel 17X-Rays 16Doxorubicin 16aldesleukin 14Immunoglobulin G 14Disulfides 14fludarabine 13Folfox protocol 13Carboplatin 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × navitoclax × Gastrointestinal × Clear all
NCT02143401 2024-11-22

Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
29 enrolled
Gastrointestinal

Fibrosis, Hepatitis B, Hepatitis C, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡